| Jul 23 |
FDA grants fast track status to BioAtla's ozuriftamab vedotin
|
| Jul 23 |
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
| Jul 3 |
Insider Traders Lose US$67k As BioAtla Drops
|
| Jun 27 |
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
|
| May 29 |
BioAtla to Participate in the Jefferies Global Healthcare Conference
|
| May 23 |
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May 23 |
Institutional owners may consider drastic measures as BioAtla, Inc.'s (NASDAQ:BCAB) recent US$35m drop adds to long-term losses
|
